A proteomic analysis using an animal model for hyperlipidemia-related erectile dysfunction.

Area of Science:

• Biochemistry
• Proteomics
• Urology

Background:

• Hyperlipidemia is linked to erectile dysfunction (ED).
• Understanding the molecular mechanisms of hyperlipidemia-related ED is crucial.
• Phosphodiesterase-5 (PDE5) inhibitors are a common ED treatment.

Purpose of the Study:

• To investigate the pathogenesis of hyperlipidemia-related ED.
• To analyze the effects of DA-8159, a novel PDE5 inhibitor, on protein expression in the corpus cavernosum.

Main Methods:

• Proteomic analysis using two-dimensional electrophoresis-mass spectrometry.
• Induction of hyperlipidemia in rats via a high-cholesterol diet.
• Treatment with DA-8159 (5 mg·kg⁻¹·day⁻¹) concurrently with the diet.

Main Results:

• Hyperlipidemia induced significant ED and altered expression of 8 proteins in the corpus cavernosum after 5 months.
• DA-8159 treatment restored protein expression levels.
• Specific proteins downregulated included alcohol dehydrogenase, aldolase A, annexin 1, and tropomyosin-rat.
• Specific proteins upregulated included aldehyde dehydrogenase complex, guanine deaminase, creatine kinase-B, and phosphoglycerate mutase type B subunit.

Conclusions:

• Hyperlipidemia causes ED through specific protein expression changes in the corpus cavernosum.
• DA-8159 effectively reverses these molecular alterations and improves erectile function.
• DA-8159 shows therapeutic potential for hyperlipidemia-related ED.